<DOC>
	<DOCNO>NCT00625651</DOCNO>
	<brief_summary>This phase 1/2 , multi-center , randomize , double-blind , placebo-controlled trial design evaluate efficacy safety AMG 655 combine mFOLFOX6 bevacizumab compare mFOLFOX6 bevacizumab alone subject previously untreated metastatic colorectal cancer ( CRC ) . The clinical benefit AMG 655 combination mFOLFOX6 bevacizumab measure progression-free survival , objective response rate , time response , duration response , overall survival . This study also design evaluate safety tolerability AMG 655 combination mFOLFOX6 bevacizumab evaluate anti-AMG 655 antibody formation pharmacokinetics AMG 655 .</brief_summary>
	<brief_title>Phase 1b/2 Study AMG 655 With mFOLFOX6 Bevacizumab First-Line Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically cytologically confirm metastatic adenocarcinoma colon rectum . Subjects measurable unmeasurable disease Eastern Cooperative Oncology Group ( ECOG ) score 0 1 Men woman least 18 year age Adequate hematologic , renal , hepatic coagulation function History know presence central nervous system ( CNS ) metastases Prior chemotherapy systemic therapy advance metastatic CRC Any investigational agent therapy advance metastatic CRC Clinically significant cardiac disease Clinically significant peripheral neuropathy Active inflammatory bowel disease Recent gastrointestinal ulcer hemorrhage Recent arterial thrombotic event pulmonary embolus Recent history clinically significant bleeding , bleed diathesis , coagulopathy Recent major surgical procedure yet recover major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Colon Cancer</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>AMG 655</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Modified FOLFOX6</keyword>
	<keyword>mFOLFOX6</keyword>
	<keyword>FOLFOX</keyword>
</DOC>